GLG News by Gardasil Prescribers (US)

Novartis is developing vaccines for diseases for which there are no current products available. Group B Strep, N. meningitidis Group B and H. Pylori are all common pathogens and cause significant morbidity.

Or whatever the total cost of Erbitux is that is required to get you four more weeks of life.  This is basically what it comes down to.  Most cost-benefit analyses will justify up to $60K spent per year of life in amortized costs, but not above that.  So the total costs of Erbitux...

-Glaxo's pre-pandemic flu vaccine is a double opportunity - a chance to contract now with multiple governments to supply a pre-pandemic vaccine as well as a natural segue to become their future supplier of actual pandemic flu vaccine (when developed).  -When pandemic flu hits, the race will be...

Glaxo's new pandemic flu vaccine was just approved for sale and use in the EU.  It has or is trying to establish contracts with multiple countries to supply stockpiles with values in the 100's of millions

This article summarizes in a concise format what most of us do anyway. Nonetheless, it is good to have the steps clearly spelled out.    

I'd go with the second analyst in the article, who points out the exosting product overlap between the two companies.

The major effect, I would hope, would be to keep people from using unlicensed practitioners to do unapproved procedures with inappropriate products.

Strattera has been approved for "maintenance treatment" for ADHD, however this probably changes nothing for prescribers or patients.  Those who are on it will continue to take it, but no one will be changing to Strattera because of this new classification.

My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.

While this is new data from an 18 month study, the common practice already is to "stick with what works." Thus, if a child is started on Strattera (or another ADHD medication) and has positive results, the physician will most likely continue that drug.